METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
METiS Therapeutics (HKG: 7666) announced on August 31, 2026 a partnership with Jiangsu Hengrui Pharmaceuticals...
Others
Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30
Ascletis Pharma Inc. (HKG: 1672) announced that the first participant has been dosed in the...
Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT‑i
Shionogi & Co., Ltd. (TYO: 4507) announced that it has terminated its collaboration with SUSMED...
Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal
Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced that the New Drug Application (NDA) for...
CrystalO Biopharma Signs Collaboration and Licensing Deal With Almirall for AI‑Driven Skin Disease Drug Discovery, Worth Up to €254.5 Million
CrystalO Biopharma Co., Ltd. announced that it has entered into a collaboration and licensing agreement...
China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion
The Joint Procurement Office published the official winning results for the 12th batch of National...
Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children
Merck & Co., Inc. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration...
Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
Luye Pharma Group Limited (HKG: 2186) announced that its independently developed new molecular entity LY03015...
AstraZeneca and Bristol-Myers Squibb Explore $400B Mega-Merger to Reshape Global Pharma Landscape
AstraZeneca plc (NYSE: AZN) is in advanced discussions with U.S. rival Bristol-Myers Squibb (BMS, NYSE:...
Xgene Pharmaceutical Secures $35M Series D Funding to Advance Non-Opioid Pain Therapy XG005 into Phase III Trials in the US
Xgene Pharmaceutical Inc. announced the successful completion of a RMB 250 million ($35 million) Series...
Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline
Nanjing Delova Biotech Co., Ltd. announced the completion of its Series C equity financing of...
DP Technology, Excalipoint Therapeutics Launch AI Antibody Discovery Platform Through Strategic Partnership Focused on T-Cell Engagers
DP Technology and Excalipoint Therapeutics announced a strategic partnership to co-develop a dedicated AI Antibody...
Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721
Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...
AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy
Wainua (eplontersen sodium injection), jointly developed by AstraZeneca plc (NYSE: AZN) and Ionis Pharmaceuticals (NASDAQ:...
OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model
OTR Therapeutics announced a strategic collaboration with LG Chem (KRX: 051910) to jointly accelerate the...
Biocytogen and Whitehawk Forge Global BsADC Partnership to Accelerate Next-Generation Cancer Therapies
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) and Whitehawk Therapeutics, Inc. (NASDAQ: WHWK)...
Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology
Novartis (NYSE: NVS) announced an agreement to acquire Myricx Bio, a privately held UK-based biotechnology...
China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways
China’s National Medical Products Administration (NMPA) has issued two landmark regulatory guidelines—the Guideline on the...
Bio-heart Secures NMPA Approval for Bioheart Biodegradable Drug-Eluting Stent – First Fully Absorbable Coronary Stent in China
Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced that China’s National Medical Products Administration (NMPA)...
Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)
Samsung Biologics (KRX: 207940) and Organon (NYSE: OGN) announced an expansion of their strategic biosimilars...